AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
mitoguazone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antineoplastics, nucleotoxic agents | 3362 | 459-86-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AKT1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHA2,EPHB4,ERBB2,FGFR1,FLT1,FLT3,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,JAK3,KIT,MAP2K1,MAP2K6,MAP3K1,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK1,MAPK10,MAPK12,MAPK14,MAPK7,MAPK9,MAPKAPK2,MARK4,MELK,MET,MTOR,NTRK2,PAK4,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIM2,PLK1,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 78 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,AXL,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K3,MAP2K6,MAP3K14,MAP3K21,MAPK7,SIK2,STK33,TEK,TGFBR1,TTK,UHMK1,ULK1 | 24 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
None
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | L01XX16 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ANTINEOPLASTIC AGENTS OTHER ANTINEOPLASTIC AGENTS Other antineoplastic agents |
| MeSH PA | D000970 | Antineoplastic Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| CHEBI has role | CHEBI:35610 | antineoplastic agent |
| CHEBI has role | CHEBI:68495 | apoptosis inducer |
| CHEBI has role | CHEBI:78024 | EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor |
Related Drugs by ATC class:
L01XX Other antineoplastic agents 33 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 8.72 | Basic |
| pKa2 | 8.02 | Basic |
| pKa3 | 2.45 | Basic |
| pKa4 | 1.45 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| S-adenosylmethionine decarboxylase proenzyme | Enzyme | IC50 | 6 | CHEMBL | |||||
| Amiloride-sensitive amine oxidase [copper-containing] | Enzyme | IC50 | 5.82 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| D07258 | KEGG_DRUG |
| C0026251 | UMLSCUI |
| CHEBI:43996 | CHEBI |
| MGB | PDB_CHEM_ID |
| CHEMBL216913 | ChEMBL_ID |
| DB12967 | DRUGBANK_ID |
| D008935 | MESH_DESCRIPTOR_UI |
| 5351154 | PUBCHEM_CID |
| 2453 | INN_ID |
| OD5Q0L447W | UNII |
| 006109 | NDDF |
| OD5Q0L447W | INXIGHT DRUGS |
Pharmaceutical products:
None